CRIS Current Research Information System

TESTONI, NICOLETTA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 12.351
NA - Nord America 11.983
EU - Europa 9.254
AF - Africa 797
SA - Sud America 556
OC - Oceania 16
Continente sconosciuto - Info sul continente non disponibili 9
Totale 34.966
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.835
VN - Vietnam 4.011
CN - Cina 3.073
SG - Singapore 2.903
GB - Regno Unito 2.264
DE - Germania 1.476
SE - Svezia 1.370
IT - Italia 1.221
HK - Hong Kong 705
FR - Francia 590
IN - India 537
RU - Federazione Russa 428
BR - Brasile 393
NL - Olanda 360
IE - Irlanda 310
UA - Ucraina 278
KR - Corea 265
ZA - Sudafrica 208
FI - Finlandia 200
JP - Giappone 184
TG - Togo 184
EE - Estonia 160
CI - Costa d'Avorio 159
CH - Svizzera 129
BG - Bulgaria 105
JO - Giordania 97
CA - Canada 95
NG - Nigeria 93
SC - Seychelles 89
GR - Grecia 88
PH - Filippine 79
AR - Argentina 73
BE - Belgio 63
BD - Bangladesh 60
TR - Turchia 53
TH - Thailandia 52
AT - Austria 48
ID - Indonesia 45
IR - Iran 44
IQ - Iraq 40
PL - Polonia 40
TW - Taiwan 36
MX - Messico 31
MY - Malesia 29
EC - Ecuador 23
ES - Italia 22
SA - Arabia Saudita 21
UZ - Uzbekistan 19
CL - Cile 18
PK - Pakistan 17
RO - Romania 16
PY - Paraguay 15
LB - Libano 14
MA - Marocco 14
HR - Croazia 13
AU - Australia 12
LT - Lituania 12
CZ - Repubblica Ceca 11
KE - Kenya 11
VE - Venezuela 11
CO - Colombia 9
PE - Perù 9
PT - Portogallo 9
TM - Turkmenistan 8
MU - Mauritius 7
RS - Serbia 7
DZ - Algeria 6
EG - Egitto 6
ET - Etiopia 6
EU - Europa 6
IL - Israele 6
PS - Palestinian Territory 6
QA - Qatar 6
AL - Albania 5
KZ - Kazakistan 5
OM - Oman 5
PA - Panama 5
TN - Tunisia 5
AE - Emirati Arabi Uniti 4
AZ - Azerbaigian 4
BB - Barbados 4
KH - Cambogia 4
MK - Macedonia 4
NP - Nepal 4
NZ - Nuova Zelanda 4
SK - Slovacchia (Repubblica Slovacca) 4
A2 - ???statistics.table.value.countryCode.A2??? 3
BA - Bosnia-Erzegovina 3
CY - Cipro 3
DK - Danimarca 3
DO - Repubblica Dominicana 3
JM - Giamaica 3
KG - Kirghizistan 3
LU - Lussemburgo 3
UY - Uruguay 3
BO - Bolivia 2
BY - Bielorussia 2
GA - Gabon 2
KW - Kuwait 2
LK - Sri Lanka 2
Totale 34.937
Salva come PNG Salva come JPEG
Città #
Singapore 2.026
Southend 2.022
Ashburn 1.267
Chandler 1.114
Fairfield 1.069
Dong Ket 1.028
Ho Chi Minh City 712
Hong Kong 670
San Jose 655
Hanoi 597
Houston 542
Woodbridge 540
Wilmington 519
Hefei 516
Ann Arbor 496
Seattle 490
Beijing 482
Frankfurt am Main 434
Princeton 380
Cambridge 375
Santa Clara 314
Dublin 309
Boardman 264
Seoul 217
Bologna 216
Lauterbourg 196
Lomé 184
Westminster 181
New York 179
Nanjing 177
Dallas 167
Padova 164
Abidjan 158
Helsinki 156
Los Angeles 151
Tokyo 144
Jacksonville 117
Berlin 116
Milan 113
Bern 106
Sofia 98
Jinan 95
Turin 95
Amman 94
Buffalo 91
Munich 91
Medford 89
Haiphong 88
Shenyang 82
Bremen 78
Saint Petersburg 76
Hebei 75
Da Nang 72
Redondo Beach 67
Abeokuta 64
Brussels 62
Guangzhou 62
Changsha 59
Florence 59
San Diego 58
Nanchang 57
Falls Church 56
Shanghai 54
Falkenstein 51
Tianjin 50
Bengaluru 49
São Paulo 46
Redwood City 41
Secaucus 41
Jiaxing 40
Johannesburg 40
Council Bluffs 39
Hangzhou 39
Redmond 39
Biên Hòa 38
Zhengzhou 38
Orem 37
Hải Dương 36
Chicago 32
Phoenix 32
Paris 31
Norwalk 30
Toronto 30
London 29
Chengdu 28
Istanbul 28
Taizhou 28
Can Tho 26
Mülheim 26
Hyderabad 25
Nuremberg 25
Warsaw 25
Thái Nguyên 24
Wuhan 24
Athens 23
Des Moines 23
Düsseldorf 23
Jakarta 23
Kyiv 23
Mountain View 23
Totale 22.490
Salva come PNG Salva come JPEG
Nome #
14q32 rearrangements deregulating BCL11B mark a distinct subgroup of T-lymphoid and myeloid immature acute leukemia 763
Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma 708
Aneuploid acute myeloid leukemia exhibits a signature of genomic alterations in the cell cycle and protein degradation machinery 383
Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience 351
B-cell acute lymphoblastic leukemia as evolution of a 8p11 myeloproliferative syndrome with t(8;22)(p11;q11) and BCR-FGFR1 fusion gene. 342
A NEW SUBSET OF ADULT B CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENT WITH PREDNISONE-INDUCED MONOCYTIC DIFFERENTIATION? 335
4q12 translocations with GSX2 expression identify a CD7+ acute myeloid leukaemia subset 323
Adult "Triple Negative" ACUTE Lymphoblastic Leukemia Genome Wide Characterization 313
A Specific Pattern of Somatic Mutations Associates with Poor Prognosis Aneuploid Acute Myeloid Leukemia: Results from the European NGS-PTL Consortium 295
Chromothripsis in acute myeloid leukemia: Biological features and impact on survival 292
Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients. 283
Aggressive Aneuploid Acute Myeloid Leukemia Is Dependent on Alterations of P53, Gain of APC and PLK1 and Loss of RAD50 281
Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of patients with high risk, Philadelphia-positive, chronic myeloid leukaemia: a European LeukemiaNet study 280
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia 274
EFFICACY, FEASIBILITY AND SAFETY OF NELARABINE SAVAGE THERAPY IN ADULT RELAPSED OR REFRACTORY T CELL ACUTE LYMPHOBLASTIC LEUKEMIA (T-ALL) OR LYMPHOBLASTIC LYMPHOMA (T-LBL): THE BOLOGNA EXPERIENCE 272
Efficacy and clinical outcome of Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL) patients treated with second generation tyrosine kinase inhibitors (TKIs): The Bologna experience 261
Alterations in phosphatidylinositol 3-phosphate (PI3P) pathway and cAMP pathway confirm poor prognosis and reduced overall survival (OS) in a series of 209 acute myeloid leukemia patients 258
The alteration in key regulator genes of autophagy is mainstream mechanism of therapy resistance and impact prognosis of acute myelogenous leukemia (AML): results from diagnosis genomic analysis on 148 consecutive patients treated with intensive chemotherapy and long-term survival follow-up 255
Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia 253
Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis 253
Alterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML) 248
Alterations of BRCA1 and PALB2 Define a Novel Class of Complex-Karyotype AML with a Very Bad Prognosis 247
Positron emission tomography with computed tomography-based diagnosis of massive extramedullary progression in a patient with high-risk multiple myeloma. 246
BCR-ABL1-associated reduction of beta catenin antagonist Chibby1 in chronic myeloid leukemia. 241
Adult B-Cell Precursor Acute Lymphoblastic Leukemia (BC-ALL) Negative For Recurrent Fusion Genes Are Characterized By a High Complex Genetic Heterogeneity Influencing Prognosis 241
Molecular response to imatinib in late chronic-phase chronic myeloid leukemia 239
Epigenetically induced ectopic expression of uncx impairs the proliferation and differentiation of myeloid cells 238
Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia 236
Chromothripsis in Acute Myeloid Leukemia Is Strongly Associated with Poor Prognosis and TP53 Alterations 231
Novel and rare fusion transcripts involving transcription factors and tumor suppressor genes in acute myeloid leukemia 231
Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implications. 228
A cell cycle-related genomic and transcriptomic signature distinguish aneuploid and euploid acute myeloid leukemia 228
Philadelphia positive (Ph+) acute lymphoblastic leukemia (ALL) patient with breast infiltration 227
MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia 224
Efficacy and Feasibility of Nelarabine Savage Therapy In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) Strongly Indicates the Introduction of a Nelarabine-Based First Line Regimen 222
CLINICAL OUTCOMES PREDICTION FOR NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH THALIDOMIDE-DEXAMETHASONE AND AUTOLOGOUS STEM CELL TRANSPLANTATION BY 8-GENE SIGNATURE OF CD138+ PLASMA CELLS 221
Efficacy and Feasibility of Nelarabine Savage Therapy In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) Strongly Indicates the Introduction of a Nelarabine-Based First Line Regimen 217
Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: Molecular cytogenetic characterization and influence on TKIs therapy 214
A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: retrospective analysis of 530 patients. 213
A novel t(2;10)(q31;p12) balanced translocation in acute myeloid leukemia 211
Identification of a novel t(1;9)(q11;q34) in acute myelocytic leukemia 208
Distinct pattern of alterations in tp53 mutated and wild type acute myeloid leukemia (AML) patients 208
Complex chromosomal rearrangements leading to MECOM overexpression are recurrent in myeloid malignancies with various 3q abnormalities 208
Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment. 206
Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study 205
Copy number variants signature in two patients with relapsed acute promyelocytic leukemia 204
Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib. 203
Mesenchymal stromal cells from myelodysplastic and acute myeloid leukemia patients display in vitro reduced proliferative potential and similar capacity to support leukemia cell survival 203
Deficient necroptosis pathway as a negative prognostic factor in acute myeloid leukemia. 200
Impact of infectious comorbidity and overall time of hospitalization in total outpatient management of acute myeloid leukemia patients following venetoclax and hypomethylating agents 198
ACTIVATION-INDUCED CYTIDINE DEAMINASE IS ABERRANTLY OVEREXPRESSED IN BCRABL1 POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA CELLS AND PROMOTES DNA-SINGLE STRAND BREAKS 198
Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. 197
Prognostic impact of serial measurements of serum-free light chain assay throughout the course of newly diagnosed multiple myeloma treated with bortezomib-based regimens 197
Opposite activation of the Hedgehog pathway in CD138+ plasma cells and CD138-CD19+ B cells identifies two subgroups of patients with multiple myeloma and different prognosis 197
CLINICAL OUTCOME OF T-ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOMA (T-ALL/TLBL): THE BOLOGNA EXPERIENCE 196
t(5;12)(q31;p13)/ETV6::ACSL6 and t(6;9)(p23;q34)/DEK::NUP214 concurrence in acute myeloid leukemia: an unusual association of two rare abnormalities 195
Circulating Multiple Myeloma Cells (CMMCs) as Prognostic and Predictive Markers in Multiple Myeloma and Smouldering MM Patients 193
Evaluation of bone disease in multiple myeloma patients carrying the t(4;14) chromosomal translocation. 192
Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response, a study of the GIMEMA CML WP. 192
Impact on survival of catastrophic karyotype events in 101 consecutive acute myeloid leukemia (AML) patients: High risk karyotype and chromothripsis 191
Association of 3q21q26 syndrome with different RPN1/EVI1 fusion transcripts 191
MHC-I Antigen Presentation Role in Immune Escape of Acute Myeloid Leukemia with High Burden of Genomic Aberration 190
Microarray analysis to identifiy novel copy number alterations in acute myeloid leukemia 190
SIRPB1 Is a Strong Predictor Biomarker of Response to 5-Azacitidine Therapy in MDS and AML Patients 188
EFFICACY AND CLINICAL OUTCOME OF PHILADELPHIA (PH) POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS TREATED WITH SECOND GENERATION TYROSINE KINASE INHIBITORS (TKIS): THE BOLOGNA EXPERIENCE 188
Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response 187
Loss of PALB2 predicts poor prognosis in acute myeloid leukemia and suggests novel therapeutic strategies targeting the DNA repair pathway 187
Role of serum-free light chain assay for defining response and progression in immunoglobulin secretory multiple myeloma 185
Dissecting the Molecular Mechanisms of Aneuploidy in Acute Myeloid Leukemia By Next Generation Sequencing 185
Acute promyelocytic leukemia with amplification of PML-RARalpha rearrangement:clinical implications 183
Maintenance therapy with bortezomib and dexamethasone after autotransplantation for high-risk multiple myeloma 183
Fludarabine, Cytarabine, Idarubicin and Etoposide (FLAIE) schedule is safe and active for young patients with newly diagnosed acute myeloid leukemia (AML): Results of a multicentric phase III Italian study 182
Gemtuzumab-Ozogamicin Containing Regimens As Induction Therapy Give the Highest Complete Remission Rate and the Longest Overall Survival Compared with Other Induction Regimens in Patients with Newly Diagnosed Acute Myeloid Leukemia 182
NPM1 mutations are more stable than FLT3 mutations during the course of disease in patients with acute myeloid leukemia. 181
Molecular and chromosomal alterations: new therapies for relapsed acute myeloid leukemia. 181
Complex karyotype, older age, and reduced first-line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long-term follow-up 180
Ponatinib Is Well Tolerated and Active In Patients With Relapsed/Refractory Philadelphia Positive Acute Lymphoblastic Leukemia (PH+ ALL) and Advanced Phase Of Chronic Myelogenous Leukemia (CML) Harbouring T315I Mutation: The Bologna Experience 179
Molecular and cytogenetic characterization of a new case of t(5;17)(q35;q21) variant acute promyelocytic leukemia 177
Very Poor Outcome and Chemoresistance of Acute Myeloid Leukemia Patients with TP53 Mutations: Correlation with Complex Karyotype and Clinical Outcome 177
Efficacy and clinical outcome of Philadelphia positive Acute Lymphoblastic Leukemia patients treated with second generation tyrosine kinase inhibitors (TKIS): the Bologna experience 176
Poor outcome with front-line autologous transplantation in t(4;14) multiple myeloma: low complete remission rate and short duration of remission. 176
Influence of additional cytogenetic abnormalities on the response and survival in late chronic phase chronic myeloid leukemia patients treated with imatinib: long-term results. 175
Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML. 175
RNA Sequencing Reveals Novel and Rare Fusion Transcripts in Acute Myeloid Leukemia 174
Prognostic significance of alterations of pathways regulating autophagy in acute myeloid leukemia 174
Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis. 174
A New Entity of Acute Myeloid Leukemia Driven By Epigenetic and Somatic Dis-Regulation of Uncx, a Novel Homeobox Transcription Factor Gene 174
TP53 mutations are mutually exclusive with FLT3 and NPM mutations in AML patients and are strongly associated with complex karyotype and poor outcome 174
Interleukin-12 production by leukemia-derived dendritic cells counteracts the inhibitory effect of leukemic microenvironment on T cells. 173
Two or More Chemotherapy Consolidation Courses, Followed By Autologous Bone Marrow Transplantation, and MRD Negativity, Give Long Term Overall Survival in Acute Myeloid Leukemia Patients 173
Revealing very small FLT3 ITD mutated clones by ultra-deep sequencing analysis has important clinical implications in AML patients 171
Imatinib Mesylate Determines a High Frequency of Major Molecular Responses in Newly Diagnosed Philadelphia Chromosome-Positive Chronic Phase Chronic Myeloid Leukemia on Behalf of the GIMEMA CML WP. 170
The baseline comorbidity burden affects survival in elderly patients with acute myeloid leukemia receiving hypomethylating agents: Results from a multicentric clinical study 169
High level of circulating cell-free tumor DNA at diagnosis correlates with disease spreading and defines multiple myeloma patients with poor prognosis 169
Efficacy of Azacitidine in the treatment of adult patients aged 65 years or older with AML 169
CLINICAL OUTCOME OF T- ACUTE LYMPHOBLASTIC LEUKEMIA/ LYMPHOMA (T-ALL/T-LBL): THE BOLOGNA EXPERIENCE 168
Cytoplasmic mutated nucleophosmin (NPM1) in blast crisis of chronic myeloid leukaemia. 167
Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. 167
Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. 167
The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase. 166
Totale 22.466
Salva come PNG Salva come JPEG
Categoria #
all - tutte 88.262
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 88.262
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.691 0 0 0 0 0 0 0 0 0 0 206 1.485
2021/20224.118 560 95 232 405 372 235 70 266 176 327 700 680
2022/20234.502 496 728 239 593 316 382 127 234 701 112 377 197
2023/20241.259 65 166 74 141 87 315 67 102 34 75 77 56
2024/20254.697 158 609 379 323 531 181 531 157 34 471 253 1.070
2025/202610.880 968 1.471 924 726 1.112 915 988 418 2.299 954 105 0
Totale 35.559